Sotera Health (NASDAQ:SHC) Holdings Trimmed by Gtcr LLC

Gtcr LLC lowered its position in shares of Sotera Health (NASDAQ:SHC) by 16.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,215,301 shares of the company’s stock after selling 10,000,000 shares during the quarter. Sotera Health accounts for 64.1% of Gtcr LLC’s investment portfolio, making the stock its largest holding. Gtcr LLC owned 17.38% of Sotera Health worth $821,896,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in SHC. CWM LLC grew its stake in shares of Sotera Health by 86.1% during the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after purchasing an additional 993 shares during the period. GAMMA Investing LLC grew its position in Sotera Health by 125.0% during the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after buying an additional 1,660 shares during the period. Capital Performance Advisors LLP purchased a new position in Sotera Health in the third quarter valued at about $91,000. Point72 DIFC Ltd lifted its position in shares of Sotera Health by 556.6% during the 2nd quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock valued at $78,000 after acquiring an additional 5,544 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of Sotera Health by 728.0% during the 2nd quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock worth $111,000 after acquiring an additional 8,248 shares in the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. The trade was a 16.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 55.12% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Barclays raised their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research note on Thursday, November 21st. Finally, Citigroup boosted their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sotera Health presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Sotera Health Stock Performance

NASDAQ:SHC opened at $12.95 on Wednesday. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The firm has a market cap of $3.67 billion, a PE ratio of 51.80 and a beta of 2.08. The firm has a 50 day simple moving average of $15.46 and a 200-day simple moving average of $14.01. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business had revenue of $285.47 million for the quarter, compared to analysts’ expectations of $278.64 million. During the same period in the prior year, the company earned $0.18 EPS. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities analysts expect that Sotera Health will post 0.61 EPS for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.